Evolving developments in the management of COPD

Loading

Evolving developments in the management of COPD

07 Oct 2019
CLINICAL THEATRE
The increasing number of inhaled drugs and devices, as well as contrasting national guidelines and recommendations for pathways of care, appear to increase the complexity of COPD treatment. In particular, the introduction of LABA/LAMA and ICS/LABA/LAMA combination inhalers, and a desire to reduce the use of inhaled corticosteroids has changed the way that patients are treated. This session aims to evaluate the current evidence for optimising and de-escalating therapy in COPD management guidelines.
Speakers
Dr Toby Capstick, Consultant Pharmacist - Respiratory Medicine - Leeds Teaching Hospitals NHS Trust

SHOW COUNTDOWN

In Association With

  • Pfizer


 

Supported By

  • AIM
  • Bayer
  • Cegedimrx
  • Day-Lewis-Pharmacy
  • GPC
  • NHS-Digital
  • NHS-England
  • NPA
  • PCPA
  • PDA
  • PSNC


 

Education Partners

  • AIM
  • BD-Rowa
  • Centred-Solutions
  • CPPE
  • Day-Lewis
  • ECG
  • Flarin
  • GAMA
  • gsk
  • Health-Education-England
  • Invatech
  • JUUL
  • MSD
  • Natures-Bounty
  • NHS-Digital
  • NPA
  • Numark
  • OMRON
  • Parkinsons
  • PDA
  • PSNC
  • Real-World-Analytics
  • RPS
  • RxAdvisor
  • Scope
  • Seqirus
  • Soar-Beyond
  • Velresco
  • WELL


 

Sponsored By

  • Alphega
  • Bollore
  • CD
  • CPPE
  • emis
  • gsk
  • NHS-Digital
  • NHS-England
  • NPA
  • Numark
  • Pfizer
  • RBforHealth


 

Charity Partners

  • Arthritis
  • Pancreatic
  • Parkinsons
  • Pharmacist


 

Official Media Partner

  • CIG


 

Official Publications

  • Independent
  • P3Pharmacy
  • Pharmacy
  • Pharmacy-Network
  • TM


 

Digital Media Partner

  • CD


 

Natural Education Partner

  • NPB


 

Media Partners

  • Guidelines
  • Pharmacy-Business
  • Pharmacy-In-Focus
  • PharmacyTalk
  • PharmData
  • PM
  • ScottishPharmacist